FDA Approves Breakthrough KRAS Lung Cancer Drug | Philadelphia News

Philadelphia News Today | 2 Min News | The Daily News Now! · Aug 5, 2026 · 1m

FDA just approved a groundbreaking new drug that targets a previously “undruggable” lung cancer mutation — KRAS G12C — offering renewed hope for patients with this aggressive form of non-small cell lung cancer. After years of scientific breakthroughs and rigorous trials, the treatment slashes cancer growth by blocking the faulty protein driving the disease. For patients who’ve run out of options, this could mean longer survival and better quality of life — all part of the precision medicine revolution reshaping oncology. Listen in comfort:Get a discount on a Soli Pillow…